<DOC>
	<DOCNO>NCT01304602</DOCNO>
	<brief_summary>This phase I trial use combination irinotecan BKM120 patient advance colorectal cancer fail become intolerant least one line therapy advance colorectal cancer candidate irinotecan therapy .</brief_summary>
	<brief_title>A Trial Irinotecan BKM120 Previously Treated Advanced Colorectal Cancer</brief_title>
	<detailed_description>Although survival patient advanced colorectal cancer improve last two decade , overwhelming majority patient still succumb disease . It third commonly diagnosed malignancy United States . We witness significant leap understand colorectal cancer carcinogenesis well identification number prognostic predictive factor associate malignancy . With use combination chemotherapy addition target agent , median survival patient advance colorectal cancer improve 4-6 month supportive care 2 year . Molecularly directed therapy cancer hold promise personalize approach treat cancer . Increase understanding tumorigenesis result identification promise target therapy strategic approach treatment malignancy . However , even development molecularly direct treatment , therapy advance colorectal cancer remain primarily palliative nature majority patient . There definite need effective therapy , agent acceptable toxicity profile , drug could administer without significant demand time activity individual patient receive drug . This phase I trial combination irinotecan BKM120 patient advance colorectal cancer fail become intolerant least one line therapy advance colorectal cancer candidate irinotecan therapy . This study attempt estimate Maximum Tolerated Dose combination irinotecan BKM120 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm metastatic unresectable adenocarcinoma colon rectum measurable disease ( patient become resistant intolerant least oneline chemotherapy regimen eligible ) Patients previous treatment Irinotecan definite progression Irinotecan eligible provide candidate therapeutic treatment option . Definitive progression define progression disease Irinotecan within 4 week discontinue Irinotecan . ≥ 18 year old ECOG performance status ≤ 2 ( Karnofsky &gt; 60 % ) ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL Serum bilirubin within normal range ( &lt; 1.5 x IULN liver metastases present ; total bilirubin ≤ 3.0 x IULN direct bilirubin within normal range patient well document Gilbert Syndrome ) AST ( SGOT ) ALT ( SGPT ) within normal range ( ≤ 3.0 x upper limit normal liver metastasis present ) adequate renal function evidence creatinine ≤ 1.5 x IULN creatinine clearance ≥ 50 mL/min/1.73 m2 subject creatinine level institutional normal . serum calcium ( correct serum albumin ) within normal limit . Biphosphonate use malignant hypercalcemia control allow . Serum magnesium ≥ institutional low limit normal ( ILLN ) potassium within institutional normal limit . serum lipase ≤ IULN ; serum amylase ≤ IULN ; fast plasma glucose ≤ 120 mg/dL ( 6.7 mmol/L ) females childbearing potential must negative serum pregnancy test within 72 hour prior treatment . Can pregnant nursing . Males female must agree use effective contraceptive method . INR ≤ 2 Exclusion Criteria Previous treatment chemotherapy , biologic therapy , wide field radiotherapy &lt; 4 week limited field radiation palliation &lt; 2 week prior start study drug ; must recover side effect therapy Known hypersensitivity BKM120 excipients irinotecan Untreated brain metastasis . Patients metastatic CNS tumor may participate trial , patient &gt; 4 week therapy completion , clinically stable receive corticosteroid therapy Known polymorphism UGTAIA Gilbert 's syndrome Acute chronic liver , renal disease pancreatitis Medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ; ≥ CTCAE grade 3 anxiety ; meet cutoff score ≥ 10 PHQ9 cutoff ≥ 15 GAD7 mood scale , respectively , selects positive response `` 1 , 2 , 3 '' question number 9 regard potential suicidal thought PHQ9 ( independent total score PHQ9 ) Clinically significant heart disease include : Left ventricular ejection fraction ( LVEF ) &lt; 50 % determined echocardiogram ; ventricular arrhythmia except benign premature ventricular contraction ; supraventricular nodal arrhythmia require pacemaker control medication ; conduction abnormality require pacemaker ; valvular disease document compromised cardiac function ; symptomatic pericarditis ; QTc &gt; 480 msec screen ECG ( use QTcF formula ; angina pectoris require use antianginal medication History cardiac dysfunction include : acute myocardial infarction ≤ 6 month , document persistent elevated cardiac enzyme persistent regional wall abnormality assessment LVEF function ; history document congestive heart failure ( NYHA Class III IV ; document cardiomyopathy Other concurrent severe and/or uncontrolled concomitant medical condition Significant symptomatic deterioration lung function . If clinically indicate , pulmonary function test include measure predict lung volume , DLco , O2 saturation rest room air consider exclude pneumonitis pulmonary infiltrates Clinical manifestation diabetes mellitus steroidinduced diabetes mellitus Impairment GI function disease may significantly alter absorption BKM120 ; diarrhea ≥ grade 2 Major surgery ≤ 4 week prior start study drug Prior treatment P13K inhibitor ; hematopoietic colonystimulating growth factor ≤ 2 week prior start study drug ; corticosteroid ≤ 2 week prior start study drug ; chemotherapy target anticancer therapy ≤4 week ( 6 week nitrosourea , antibody mitomycinC ) prior start study drug ; small molecule therapeutic ( exclude monoclonal antibody ) ≤5 effective halflives prior start study drug Currently receive medication potential prolong QT interval induce Torsades de Pointes chronic treatment steroid another immunosuppressive agent . Note : Topical application ( eg rash ) , inhale spray ( eg obstructive airway disease ) , eye drop local injection ( eg intraarticular ) allow . Patients previously treat brain metastasis , stable low dose corticosteroid treatment ( eg dexamethasone 2 mg/day , prednisolone 10 mg/day ) least 14 day start study treatment eligible . therapeutic dos warfarin sodium coumadinderivative anticoagulant . medication substances inhibitor inducer specific CYP450 enzyme ( ) . study agent Patients take herbal medication certain fruit within 7 day prior start study drug . Herbal medication include , limited St. John 's wort , Kava , ephedra ( huang ) , gingko biloba , dehydroepiandrosterone ( DHEA ) , yohimbe , saw palmetto , ginseng . Fruits include CYP3A inhibitor Seville orange , grapefruit , pummelo , exotic citrus fruit . Patients receive wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug recover side effect therapy Women pregnant breast feeding ; adult reproductive potential use effective method birth control . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( eg age appropriate , history vasomotor symptom ) 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL estradiol &lt; 20 pg/mL surgical bilateral oophorectomy ( without hysterectomy ) least 6 week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Women childbearing potential , defined woman physiologically capable become pregnant , must use highly effective contraception treatment 8 day stop treatment additional 12 week study drug discontinuation . Highly effective contraception define : true abstinence : Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Sterilization : surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least 6 week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male partner sterilization ( appropriate postvasectomy documentation absence sperm ejaculate ) . For female subject study , vasectomise male partner sole partner patient . Use combination two follow ( a+b ) : Placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository ; Oral contraception , inject implanted hormonal method allow BKM120 potentially decrease effectiveness hormonal contraceptive . Fertile male must use condom treatment , 8 day stop treatment additional 12 week study drug discontinuation father child period . Known diagnosis human immunodeficiency virus ( HIV ) infection History another malignancy within 3 year , except cure basal cell skin carcinoma excise cervical carcinoma situ Previous treatment Irinotecan definite progression Irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>BKM120</keyword>
	<keyword>irinotecan</keyword>
</DOC>